Peptic ulcer disease

Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.Full text  Abstract

Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.Full text  Abstract

Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text  Abstract

Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021 May 1;116(5):899-917. Abstract

1. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1;29(9):938-46.Full text  Abstract

2. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol. 2010 Aug 24;105(12):2570-7. Abstract

3. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol. 2006 Jun 1;163(11):1025-34. Abstract

4. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 Suppl 2:3-12. Abstract

5. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology. 2007 Jun;132(7):2320-7.Full text  Abstract

6. Cai S, García Rodríguez LA, Massó-González EL, et al. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1039-48.Full text  Abstract

7. Nam K, Shin JE, Kim SE, et al. Prevalence and risk factors for upper gastrointestinal diseases in health check-up subjects: a nationwide multicenter study in Korea. Scand J Gastroenterol. 2018 Aug;53(8):910-6. Abstract

8. Suerbaum S, Michetti P. Helicobacter pylori infection. New Engl J Med. 2002 Oct 10;347(15):1175-86. Abstract

9. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002 Jan 5;359(9300):14-22. Abstract

10. Hung LC, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology. 2005 Jun;128(7):1845-50. Abstract

11. Dore MP, Soro S, Niolu C, et al. Clinical features and natural history of idiopathic peptic ulcers: a retrospective case-control study. Scand J Gastroenterol. 2019 Nov;54(11):1315-21. Abstract

12. O'Connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol Suppl. 1994;201:11-5. Abstract

13. Cekin AH, Taskoparan M, Duman A, et al. The role of Helicobacter pylori and NSAIDs in the pathogenesis of uncomplicated duodenal ulcer. Gastroenterol Res Pract. 2012;2012:189373.Full text  Abstract

14. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional nonsteroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004 Jul;20(suppl 2):48-58. Abstract

15. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad Med J. 2001 Feb;77(904):82-8.Full text  Abstract

16. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr. 2017 Jun;40(3):91-3.Full text  Abstract

17. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948. Abstract

18. Tang CL, Ye F, Liu W, Pan XL, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012 Aug;17(4):286-96. Abstract

19. Garrow D, Delegge MH. Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci. 2009 Jan 22;55(1):66-72. Abstract

20. Maity P, Biswas K, Roy S, et al. Smoking and the pathogenesis of gastroduodenal ulcer--recent mechanistic update. Mol Cell Biochem. 2003 Nov;253(1-2):329-38. Abstract

21. Brenner H, Rothenbacher D, Bode G, et al. The individual and joint contributions of Helicobacter pylori infection and family history to the risk for peptic ulcer disease. J Infect Dis. 1998 Apr;177(4):1124-7. Abstract

22. Johnsen R, Førde OH, Straume B, et al. Aetiology of peptic ulcer: a prospective population study in Norway. J Epidemiol Community Health. 1994 Apr;48(2):156-60. Abstract

23. Del Bianco T, Borgoni R, Del Bianco P, et al. Peptic ulcer inheritance in patients with elevated serum pepsinogen group A levels and without infection of Helicobacter pylori. Dig Liver Dis. 2000 Jan-Feb;32(1):12-9. Abstract

24. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002 Jun;30(suppl 6):S373-8. Abstract

25. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802.Full text  Abstract

26. Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jan 25;33(6):973-80. Abstract

27. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728-38. Abstract

28. Alshamsi F, Belley-Cote E, Cook D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016 May 4;20(1):120.Full text  Abstract

29. Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med. 2017 Dec 4;44(1):1-11.Full text  Abstract

30. Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2016 Sep 15;152(1):105-10.e1. Abstract

31. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.Full text  Abstract

32. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.Full text  Abstract

33. ASGE Standards of Practice Committee, Banerjee S, Cash BD, Dominitz JA, et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc. 2010 Apr;71(4):663-8.Full text  Abstract

34. National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. November 2019 [internet publication].Full text

35. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text  Abstract

36. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64.Full text  Abstract

37. Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;(3):CD012080.Full text  Abstract

38. McNulty C, Teare L, Owen R, et al. Test and treat for dyspepsia--but which test? BMJ. 2005 Jan 15;330(7483):105-6.Full text  Abstract

39. Centers for Disease Control and Prevention (CDC). Health information for international travel (Yellow Book). Chapter 4: travel-related infectious diseases, Helicobacter pylori. Jun 2019 [internet publication].Full text

40. Public Health England. Helicobacter pylori in dyspepsia: test and treat. Sept 2019 [internet publication].Full text

41. Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021 May 1;116(5):899-917. Abstract

42. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med. 2019 Dec 3;171(11):805-22.Full text  Abstract

43. Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. ANZ J Surg. 2007 Aug;77(8):677-81. Abstract

44. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 7;150(7):455-64.Full text  Abstract

45. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000 Aug 3;343(5):310-6.Full text  Abstract

46. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol. 2022 Apr 1;117(4):542-58.Full text  Abstract

47. Cheung J, Rajala J, Moroz D, et al. Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding. Can J Gastroenterol. 2009 Sep;23(9):619-23.Full text  Abstract

48. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1-9. Abstract

49. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21.Full text  Abstract

50. Dahal K, Sharma SP, Kaur J, et al. Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther. 2017 Sep/Oct;24(5):e559-e569. Abstract

51. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016 Nov 13;375(26):2519-29.Full text  Abstract

52. Richardson C, Hawkey CJ, Stack WA. Proton pump inhibitors - pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998 Sep;56(3):307-35. Abstract

53. Lykkegaard Nielsen MC, Vagn Nielsen O, Moesgaard F. Ulcer healing after treatment with sucralfate emulsion or ranitidine. Randomized controlled study in peptic ulcer disease. J Clin Gastroenterol. 1988 Aug;10(4):377-9. Abstract

54. Rey JF, Legras B, Verdier A, et al. Comparative study of sucralfate versus cimetidine in the treatment of acute gastroduodenal ulcer. Randomized trial with 667 patients. Am J Med. 1989 Jun 9;86(6a):116-21. Abstract

55. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.Full text  Abstract

56. Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;(4):CD003840.Full text  Abstract

57. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2009 Sep 15;105(1):65-73. Abstract

58. Venerito M, Krieger T, Ecker T, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013 Jul 19;88(1):33-45.Full text  Abstract

59. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016;(6):CD009034.Full text  Abstract

60. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, et al. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. Abstract

61. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014 Oct;109(10):1595-602. Abstract

62. Targownik LE, Fisher DA, Saini SD. AGA Clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022 Apr;162(4):1334-42.Full text  Abstract

63. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-41.Full text  Abstract

64. Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019 May 29;365:l1580.Full text  Abstract

65. Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103-14. Abstract

66. Chrysant SG. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2019 May;17(5):345-51. Abstract

67. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50. Abstract

68. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul;5(4):219-32.Full text  Abstract

69. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013 Jul;6(4):443-51. Abstract

70. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019 Sep;157(3):682-691.e2.Full text  Abstract

71. Hansen KE, Nieves JW, Nudurupati S, et al. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019 Mar;156(4):926-934.e6.Full text  Abstract

72. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337.Full text  Abstract

73. ClinicalTrials.gov. ERADICATE Hp - Treating Helicobacter pylori With RHB-105 (ERADICATE Hp). ClinicalTrials.gov Identifier: NCT01980095. Sept 2019 [internet publication].Full text

74. ClinicalTrials.gov. ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2) ClinicalTrials.gov Identifier: NCT03198507. Mar 2020 [internet publication].Full text

75. Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019 Aug;24(4):e12597.Full text  Abstract

76. Boonpongmanee S, Fleischer DE, Pezzullo JC, et al. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc. 2004 Jun;59(7):788-94. Abstract

77. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text  Abstract